We seek cooperation in R&D, preclinical validation and regulatory studies to co-develop innovative solutions for the treatment of infected chronic wounds.

M2D1 is a Brazilian deep-tech company focused on developing advanced technologies for the management of infected chronic wounds. Our health project, BST22, is currently in preclinical validation and was designed to reduce microbial load, address biofilms and improve clinical outcomes through a safe, non-invasive approach.

We integrate biomedical engineering, applied microbiology, embedded intelligence and regulatory requirements to create an innovative medical device that supports healthcare professionals in treating complex wounds, including diabetic, pressure and vascular ulcers.

We seek international partners for cooperation in R&D, preclinical validation, regulatory studies and the design of future clinical trials. We are also interested in Horizon Europe consortia involving emerging medical technologies, infection management, healthy ageing and integrated care solutions.

M2D1 brings technical expertise, scientific rigor and active participation in innovation ecosystems, offering qualified contributions to high-impact collaborative health projects.